Phase I Study of Amifostine in Patients With Bone Marrow Failure Related to Fanconi's Anemia
Status unconfirmed · Phase 1
Conditions studied: Fanconi's Anemia
In brief
OBJECTIVES: I. Evaluate the toxicity of amifostine in patients with bone marrow failure related to Fanconi's anemia. II. Determine the efficacy of this treatment regimen in this patient population. III. Evaluate the effect of this treatment regimen on bone marrow progenitor cell proliferation and peripheral blood mononuclear cell apoptosis in these patients.
Key facts
- Study ID
- NCT00006127
- Run by
- Dana-Farber Cancer Institute
- People needed
- 21
- Starts
- 2000-04-01
- Last updated by the study team
- 2005-06-24
Who can join
Age: 2 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.